In this Review:
Adjuvant docetaxel improves survival in hormone-naïve advanced PCa
. . . and in high-risk, localised PCa
Mechanisms of resistance to androgen signalling inhibitors
Characterising the NEPC resistance phenotype
Immediate versus delayed ADT in PCa with a rising PSA
New CRPC clinical trial guidelines to succeed PCWG2
Please login below to download this issue (PDF)